Sun Pharmaceutical Industries has announced a Rs 3,000 crore investment to set up a greenfield formulations manufacturing facility in Madhya Pradesh.
The investment, approved by the board of Sun Pharma’s wholly-owned subsidiary, Sun Pharma Laboratories, is expected to support the company's growth strategy in the region. The move is seen as part of Sun Pharma’s larger plan to boost its manufacturing capacity and strengthen its position in the domestic and global markets. Jayashree Satagopan, the company’s CFO, had previously mentioned that Sun Pharma expects its India business to grow ahead of the market, driven by a focus on key therapies and brand development.
The expansion is expected to further enhance Sun Pharma's capabilities in the competitive pharmaceutical market, which has seen robust growth in the company’s domestic business.